Published in Lancet on January 12, 2001
The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) | NCT00292877
Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations (MATERIAL) | NCT01520051
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med (2012) 4.85
TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol (2008) 3.42
Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest (2003) 3.16
Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest (2004) 3.06
A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol (2008) 2.78
The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol (2010) 2.74
Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2012) 2.69
Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol (2010) 2.62
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol (2008) 2.04
Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med (2002) 2.04
Innate cells and T helper 2 cell immunity in airway inflammation. Immunity (2009) 1.94
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Importance of cytokines in murine allergic airway disease and human asthma. J Immunol (2010) 1.86
Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech (2008) 1.86
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax (2001) 1.76
Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax (2003) 1.75
Biology of the eosinophil. Adv Immunol (2009) 1.74
A centennial history of research on asthma pathogenesis. Am J Respir Cell Mol Biol (2005) 1.72
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy (2014) 1.65
Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol (2008) 1.64
Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma. J Exp Med (2008) 1.59
A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A (2006) 1.55
OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy (2014) 1.54
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med (2003) 1.53
CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol (2008) 1.51
Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am (2009) 1.51
Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol (2009) 1.43
Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res (2001) 1.38
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Thymic stromal lymphopoietin: a new cytokine in asthma. Curr Opin Pharmacol (2008) 1.35
The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest (2010) 1.35
Eosinophils in innate immunity: an evolving story. Cell Tissue Res (2010) 1.34
What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol (2010) 1.33
Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol (2010) 1.32
Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res (2011) 1.31
Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev (2011) 1.29
Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy (2014) 1.29
IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol (2011) 1.27
Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci (2007) 1.26
Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol (2011) 1.25
Pathology of asthma. Front Microbiol (2013) 1.25
Th2 cytokines and asthma: an introduction. Respir Res (2001) 1.24
Mechanisms of remodeling in asthmatic airways. J Allergy (Cairo) (2012) 1.20
Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest (2005) 1.20
Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol (2012) 1.14
The microbiology of asthma. Nat Rev Microbiol (2012) 1.14
Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann Intern Med (2010) 1.13
Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med (2004) 1.12
Airway remodelling in asthma: from benchside to clinical practice. Can Respir J (2010) 1.11
The potential of biologics for the treatment of asthma. Nat Rev Drug Discov (2012) 1.11
Bronchospasm and its biophysical basis in airway smooth muscle. Respir Res (2004) 1.11
Cytokine/anti-cytokine therapy - novel treatments for asthma? Br J Pharmacol (2011) 1.11
Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice. PLoS One (2009) 1.11
5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat (2009) 1.09
Analysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte. Respir Res (2011) 1.07
Overexpression of endothelial nitric oxide synthase suppresses features of allergic asthma in mice. Respir Res (2006) 1.07
Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways. Respir Res (2003) 1.06
Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J Immunol (2008) 1.05
Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov (2015) 1.05
Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest (2010) 1.03
Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J Allergy Clin Immunol (2010) 1.03
New drugs targeting Th2 lymphocytes in asthma. J Occup Med Toxicol (2008) 1.03
The effect of eosinophils on collagen gel contraction and implications for tissue remodelling. Clin Exp Immunol (2004) 1.03
Immunomodulation of allergic disease. Annu Rev Med (2009) 1.02
Importance of myeloid dendritic cells in persistent airway disease after repeated allergen exposure. Am J Respir Crit Care Med (2005) 1.02
Murine lung eosinophil activation and chemokine production in allergic airway inflammation. Cell Mol Immunol (2010) 1.01
The eosinophil enigma. J Clin Invest (2004) 1.01
Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res (2011) 1.01
Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci (2011) 1.00
Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Respir Res (2010) 1.00
Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol (2006) 1.00
Eosinophilic inflammation in allergic asthma. Front Pharmacol (2013) 1.00
Airways inflammation and treatment during acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2008) 1.00
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol (2006) 0.99
Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem (2011) 0.98
Stratified approaches to the treatment of asthma. Br J Clin Pharmacol (2013) 0.98
Using guinea pigs in studies relevant to asthma and COPD. Pulm Pharmacol Ther (2008) 0.98
Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res (2010) 0.97
Eosinophils in mucosal immune responses. Mucosal Immunol (2015) 0.97
Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest (2010) 0.96
Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet (2008) 0.96
Asthma: T-bet--a master controller? Curr Biol (2002) 0.96
Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One (2013) 0.95
Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. J Immunol (2009) 0.95
Chemokines, innate and adaptive immunity, and respiratory disease. Eur Respir J (2002) 0.95
Asthma: beyond corticosteroid treatment. Arch Med Sci (2013) 0.95
Increases in airway eosinophilia and a th1 cytokine during the chronic asymptomatic phase of asthma. Respir Med (2010) 0.94
Galectin-3: its role in asthma and potential as an anti-inflammatory target. Respir Res (2013) 0.93
Update on anticytokine treatment for asthma. Biomed Res Int (2013) 0.92
IL-22 contributes to TGF-β1-mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. Respir Res (2013) 0.92
Lactobacillus priming of the respiratory tract: Heterologous immunity and protection against lethal pneumovirus infection. Antiviral Res (2012) 0.92
Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. PLoS One (2013) 0.92
Targeting eosinophils in asthma. Curr Mol Med (2008) 0.91
Current status and challenges of cytokine pharmacology. Br J Pharmacol (2009) 0.91
Re-defining the unique roles for eosinophils in allergic respiratory inflammation. Clin Exp Allergy (2014) 0.91
Overlap Between Asthma and COPD: Where the Two Diseases Converge. Allergy Asthma Immunol Res (2010) 0.90
Pathogenesis and disease mechanisms of occupational asthma. Immunol Allergy Clin North Am (2011) 0.90
Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract (2015) 0.90
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med (2000) 9.44
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med (1990) 7.46
A self management plan in the treatment of adult asthma. Thorax (1989) 5.85
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996) 5.53
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J (2005) 5.24
Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med (1999) 4.72
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Mucosal inflammation in asthma. Am Rev Respir Dis (1990) 4.11
Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis (1989) 3.86
Subepithelial fibrosis in the bronchi of asthmatics. Lancet (1989) 3.70
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet (2001) 3.48
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med (1999) 3.44
Asthma as an axon reflex. Lancet (1986) 3.26
Prevalence of respiratory symptoms among 7 and 11 year old schoolchildren and association with asthma. Arch Dis Child (1989) 3.25
Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med (1999) 3.22
Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet (1982) 3.21
A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16
Exhaled markers of pulmonary disease. Am J Respir Crit Care Med (2001) 3.14
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med (1996) 3.10
Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J (2005) 3.05
Use of polymerase chain reaction for diagnosis of picornavirus infection in subjects with and without respiratory symptoms. J Clin Microbiol (1993) 3.01
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
The diagnosis and management of chronic cough. Eur Respir J (2004) 2.96
T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol (1996) 2.92
Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis (1992) 2.89
Rhinoviruses infect the lower airways. J Infect Dis (2000) 2.83
The MYCN oncogene is a direct target of miR-34a. Oncogene (2008) 2.80
Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J (1997) 2.79
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet (1999) 2.75
Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol (1994) 2.73
Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax (1998) 2.71
A community study of sleep-disordered breathing in middle-aged Chinese men in Hong Kong. Chest (2001) 2.66
Exacerbations of chronic obstructive pulmonary disease. Eur Respir J (2007) 2.65
Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis (1987) 2.64
Cytokines in asthma. Thorax (1999) 2.64
[Hyperventilation: not a cause of panic attacks]. Ned Tijdschr Geneeskd (1993) 2.64
Inflammatory mediators of asthma: an update. Pharmacol Rev (1998) 2.54
Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med (1995) 2.52
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med (1992) 2.52
Protection against allergen-induced asthma by salmeterol. Lancet (1990) 2.51
Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med (1995) 2.48
Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis (1990) 2.45
Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J (2000) 2.42
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ (1997) 2.40
ERS guidelines on the assessment of cough. Eur Respir J (2007) 2.36
Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax (2004) 2.36
Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med (2000) 2.33
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med (1992) 2.32
Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1996) 2.32
Augmentation of permeability in the bronchial epithelium by the house dust mite allergen Der p1. Am J Respir Cell Mol Biol (1995) 2.30
Personal exposures of children to nitrogen dioxide relative to concentrations in outdoor air. Occup Environ Med (2000) 2.29
Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 2.28
Difficult asthma. BMJ (1989) 2.28
Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ (1992) 2.25
Circulating catecholamines in exercise and hyperventilation induced asthma. Thorax (1981) 2.22
Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. Thorax (1984) 2.20
Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax (2005) 2.19
Exhaled carbon monoxide in childhood asthma. J Pediatr (1999) 2.19
Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med (1998) 2.19
Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J (2001) 2.18
Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J (2004) 2.18
Inflammatory mediators and asthma. Pharmacol Rev (1988) 2.17
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1990) 2.14
Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest (1998) 2.13
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer (2009) 2.13
Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res (2001) 2.10
Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol (1983) 2.10
COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J (2008) 2.06
Longitudinal changes in skin-prick test reactivity over 2 years in a population of schoolchildren with respiratory symptoms. Clin Exp Allergy (1992) 2.06
STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 2.06
Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Br Med J (Clin Res Ed) (1987) 2.05
The natural history of respiratory symptoms in a cohort of adolescents. Am J Respir Crit Care Med (1998) 2.05
Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J (1996) 2.05
Fatal asthma attack during an inhalation challenge with ultrasonically nebulized distilled water. J Allergy Clin Immunol (1995) 2.04
Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J (2002) 2.04
Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med (2000) 2.03
A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers (2007) 2.02